GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Reyon Pharmaceutical Co 102460.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

9,380

+0.97%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩145.93bn

FY2016FY2025

Net income

−₩29.63bn

FY2016FY2025

Free cash flow

−₩6.46bn

FY2016FY2025

Shareholders' equity

₩220.27bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩145.93bn₩148.30bn₩151.07bn₩154.04bn₩142.80bn₩130.03bn₩131.56bn₩122.99bn₩126.25bn₩121.85bn
Gross profit₩38.23bn₩72.79bn₩78.90bn₩81.73bn₩79.44bn₩72.58bn₩74.26bn₩68.52bn₩72.65bn₩70.32bn
Research and development₩3.91bn₩3.32bn₩8.38bn₩6.71bn₩9.73bn₩6.58bn₩3.72bn₩6.70bn₩3.45bn₩6.49bn
Operating income−₩30.69bn₩6.31bn₩3.08bn₩9.32bn₩3.05bn₩3.45bn₩7.90bn₩2.46bn₩16.00bn₩14.07bn
Net income−₩29.63bn₩4.15bn₩3.58bn₩7.43bn₩5.54bn₩3.84bn₩5.94bn₩1.34bn₩12.89bn₩10.70bn
Diluted earnings per share-1,792.91251.17216.81449.77335.02232.60359.4981.25768.51638.13

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩465.10bn₩499.99bn₩499.78bn₩484.69bn₩477.98bn₩317.61bn₩274.48bn₩303.17bn₩290.84bn₩209.54bn
Total liabilities₩244.83bn₩250.05bn₩251.15bn₩236.93bn₩232.74bn₩87.52bn₩52.19bn₩77.77bn₩71.18bn₩30.44bn
Debt₩99.00bn₩113.00bn₩121.00bn₩184.22bn₩182.42bn₩33.80bn₩26.60bn₩35.27bn₩68.08bn₩2.00bn
Shareholders' equity₩220.27bn₩249.94bn₩248.62bn₩247.77bn₩245.24bn₩230.09bn₩220.20bn₩223.52bn₩219.66bn₩179.10bn
Shares outstanding17m17m17m17m17m17m17m17m17m17m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩1.46bn−₩1.44bn₩8.65bn₩8.73bn₩11.68bn₩4.60bn−₩12.18bn₩11.45bn₩16.76bn₩9.47bn
Capital spending−₩7.92bn−₩16.02bn−₩28.87bn−₩63.13bn−₩116.98bn−₩52.31bn−₩50.93bn−₩39.17bn−₩4.14bn−₩3.21bn
Free cash flow−₩6.46bn−₩17.46bn−₩20.23bn−₩54.40bn−₩105.29bn−₩47.71bn−₩63.11bn−₩27.72bn₩12.62bn₩6.26bn
Dividends paid—−₩2.75bn−₩2.74bn−₩4.56bn−₩3.46bn−₩5.78bn−₩8.26bn−₩5.87bn−₩4.51bn−₩3.87bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩35.85bn₩36.05bn₩33.90bn₩37.58bn₩37.69bn₩36.76bn₩37.31bn₩38.29bn
Gross profit₩17.26bn₩9.81bn₩16.25bn₩10.17bn₩13.90bn₩21.77bn₩17.84bn₩18.70bn
Operating income−₩4.55bn−₩6.66bn−₩6.57bn−₩7.20bn−₩9.30bn₩4.12bn₩3.53bn₩1.65bn
Net income−₩6.80bn−₩10.74bn−₩12.84bn−₩3.86bn−₩13.15bn₩216.1m₩2.55bn₩619.3m
Diluted earnings per share-411.69-649.63-776.91-233.70-795.3813.07154.0537.47
Cash from operations₩8.88bn−₩2.38bn₩1.45bn−₩1.73bn−₩677.0m₩2.41bn−₩5.31bn₩1.76bn
Capital spending−₩893.0m−₩1.18bn−₩1.98bn−₩989.0m−₩699.0m−₩4.25bn—−₩6.07bn
Free cash flow₩7.99bn−₩3.56bn−₩531.0m−₩2.72bn−₩1.38bn−₩1.83bn—−₩4.32bn
Total assets₩444.37bn₩454.38bn₩465.10bn₩473.11bn₩475.75bn₩489.69bn₩499.99bn₩494.86bn
Debt₩89.50bn₩95.00bn₩99.00bn₩103.00bn₩107.00bn₩111.00bn₩113.00bn₩115.00bn
Shareholders' equity₩194.87bn₩209.58bn₩220.27bn₩233.12bn₩236.97bn₩250.08bn₩249.94bn₩247.40bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.8%2.3%2.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin37.7%45.3%48.6%52.1%
Operating margin-8.3%-2.0%-0.6%3.7%
Net margin-8.7%-2.4%-0.6%2.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-6.051.176.348.1106.195.043.6167.727.434.4
Price to sales1.21.41.82.34.12.82.01.82.83.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2023.

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Paid in the year150.00150.00250.00196.078343.137490.196343.137263.952
  • 1.02-for-1 split · 29 Dec 2020
  • 13-for-10 split · 29 Nov 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.